Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Cohen

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Journal of Clinical Medicine|January 12, 2021
Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid ObesityAlexander Cohen, Janvi Sah, Theodore Lee, et al.
Plastic and Reconstructive Surgery|April 9, 2025
Aplasia Cutis: From Diagnosis to Management- Two Decades of Clinical InsightsOfir Ron, Idan Farber, Meir Retchkiman, et al.
Thrombosis Research|July 7, 2012
Managing venous thromboembolism in Asia: winds of change in the era of new oral anticoagulantsAlexander Cohen, Kuan Ming Chiu, Kihyuk Park, et al.
Thrombosis and Haemostasis|November 10, 2020
Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data AnalysisAlexander Cohen, Allison Keshishian, Theodore Lee, et al.
Journal of Clinical Anesthesia|November 5, 2017
Selected highlights in clinical anesthesia researchMark C Kendall, Zachary M Robbins, Alexander Cohen, et al.
Frontiers in Neurology|April 10, 2025
Changes in cerebrovascular reactivity within functional networks in older adults with long-COVIDJessica M Pommy, Alexander Cohen, Amarpreet Mahil, et al.
Haematologica|August 12, 2021
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trialCecilia Becattini, Rupert Bauersachs, Giorgio Maraziti, et al.
The American Journal on Addictions|April 12, 2011
Addiction treatment provider attitudes on staff capacity and evidence-based clinical training: results from a national studyLena Lundgren, Maryann Amodeo, Ivy Krull, et al.
Plos One|May 21, 2024
Using 30-day modified rankin scale score to predict 90-day score in patients with intracranial hemorrhage: Derivation and validation of prediction modelWilliam L Baker, Mukul Sharma, Alexander Cohen, et al.
The New England Journal of Medicine|December 11, 2012
Apixaban for extended treatment of venous thromboembolismGiancarlo Agnelli, Harry R Buller, Alexander Cohen, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Journal of Clinical Medicine|January 12, 2021
Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid ObesityAlexander Cohen, Janvi Sah, Theodore Lee, et al.
Plastic and Reconstructive Surgery|April 9, 2025
Aplasia Cutis: From Diagnosis to Management- Two Decades of Clinical InsightsOfir Ron, Idan Farber, Meir Retchkiman, et al.
Thrombosis Research|July 7, 2012
Managing venous thromboembolism in Asia: winds of change in the era of new oral anticoagulantsAlexander Cohen, Kuan Ming Chiu, Kihyuk Park, et al.
Thrombosis and Haemostasis|November 10, 2020
Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data AnalysisAlexander Cohen, Allison Keshishian, Theodore Lee, et al.
Journal of Clinical Anesthesia|November 5, 2017
Selected highlights in clinical anesthesia researchMark C Kendall, Zachary M Robbins, Alexander Cohen, et al.
Frontiers in Neurology|April 10, 2025
Changes in cerebrovascular reactivity within functional networks in older adults with long-COVIDJessica M Pommy, Alexander Cohen, Amarpreet Mahil, et al.
Haematologica|August 12, 2021
Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trialCecilia Becattini, Rupert Bauersachs, Giorgio Maraziti, et al.
The American Journal on Addictions|April 12, 2011
Addiction treatment provider attitudes on staff capacity and evidence-based clinical training: results from a national studyLena Lundgren, Maryann Amodeo, Ivy Krull, et al.
Plos One|May 21, 2024
Using 30-day modified rankin scale score to predict 90-day score in patients with intracranial hemorrhage: Derivation and validation of prediction modelWilliam L Baker, Mukul Sharma, Alexander Cohen, et al.
The New England Journal of Medicine|December 11, 2012
Apixaban for extended treatment of venous thromboembolismGiancarlo Agnelli, Harry R Buller, Alexander Cohen, et al.
Pageof 5